PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Retatrutide — known in clinical literature as LY3437943 — represents one of the most structurally advanced synthetic peptide candidates to emerge from metabolic research in the past decade. As a triple receptor agonist simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, it occupies a unique mechanistic position distinct from any previously characterised compound. For licensed research institutions in Ireland, Peptides Lab Ireland provides retatrutide in lyophilised form, manufactured to stringent quality standards, for use exclusively in approved laboratory settings.
Retatrutide is a synthetic acylated peptide analogue with the molecular formula C₂₂₄H₃₅₅N₄₉O₆₈S and a molecular weight of approximately 4,759 Da. The compound is constructed on a 24-amino acid backbone engineered for simultaneous multi-receptor engagement. Its fatty acid acylation — analogous to but distinct from semaglutide’s C18 chain — provides extended plasma half-life properties that have made it particularly valuable for chronic rodent model studies requiring once-weekly or less frequent administration.
The triple agonism profile is what distinguishes retatrutide mechanistically. Where semaglutide acts solely on GLP-1R and tirzepatide adds GIP receptor engagement, retatrutide adds a third axis: glucagon receptor (GCGR) activity. Glucagon receptor stimulation in isolation typically increases hepatic glucose output — counterproductive in metabolic contexts — but when balanced against GLP-1R-mediated insulin sensitisation and GIP-mediated energy regulation, the net effect observed in preclinical and early clinical models has been amplified energy expenditure without the compensatory appetite increase seen with GCGR agonism alone.
Phase 2 clinical data published in 2023 in the New England Journal of Medicine reported findings from a 48-week, randomised, double-blind trial (NCT04881760) involving participants with overweight or obesity. At the highest studied dose, subjects in the active arm demonstrated mean body weight reductions exceeding 24% — a figure that exceeded published outcomes for both semaglutide 2.4 mg and tirzepatide 15 mg at comparable timeframes in their own pivotal trials. Researchers noted that the glucagon receptor component appeared to drive disproportionate reductions in hepatic fat fraction alongside total adiposity, making it of particular academic interest in models of metabolic-associated steatotic liver disease (MASLD).
Preclinical rodent studies preceding the Phase 2 data demonstrated dose-dependent reductions in food intake, adipose tissue mass, and fasting insulin in diet-induced obese (DIO) murine models. Crucially, lean mass preservation was studied alongside fat mass reduction, with skeletal muscle indices remaining relatively stable across dosing arms — a mechanistic area still under investigation in the research literature.
Additional areas of active preclinical investigation include:
The Irish research landscape encompasses several institutions with active metabolic disease programmes — Trinity College Dublin, University College Cork, the Royal College of Surgeons in Ireland (RCSI), and affiliated hospital research units. As the global obesity and MASH research field expands, compounds like retatrutide enable investigators to model multi-receptor metabolic interventions and compare outcomes across single, dual, and triple agonism paradigms within the same in vitro or in vivo experimental design.
Because retatrutide remains an investigational compound without any licensed therapeutic indication in Ireland or the European Union, it is classified under the HPRA framework as a research-grade substance available exclusively for in-vitro laboratory use by qualified, licensed research professionals. It is emphatically not available as a weight management or pharmaceutical intervention, and Peptides Lab Ireland makes no claims regarding therapeutic efficacy or clinical applicability.
Every batch of retatrutide supplied by Peptides Lab Ireland meets the following minimum quality benchmarks:
Retatrutide in lyophilised form should be stored at −20°C and protected from light. Repeated freeze-thaw cycling degrades peptide integrity; researchers are advised to aliquot reconstituted solutions prior to freezing. Once reconstituted, solutions should be used within 28 days when stored at 4°C or within 6 months when stored at −80°C. These parameters reflect standard peptide stability guidelines and should be adapted to individual laboratory protocols as appropriate.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide adds a third receptor target — the glucagon receptor (GCGR) — creating a triple agonist profile. This additional mechanism is hypothesised to drive greater energy expenditure via thermogenic and hepatic pathways, and has been a subject of focused research interest since the 2023 Phase 2 publication.
Retatrutide has no licensed therapeutic status in Ireland or the EU. It is not a controlled substance under the Misuse of Drugs Acts 1977–2016. It may be purchased and held for legitimate, licensed in-vitro research purposes by qualified researchers in appropriate institutional settings. It is not for human or veterinary use.
Retatrutide is a research compound only. It has no licensed therapeutic indication for any condition in Ireland. All clinical findings referenced on this page are from academic research literature and are not applicable to human self-administration. Any use outside a licensed laboratory research context would be outside the scope of supply from Peptides Lab Ireland.
Peptides Lab Ireland supplies retatrutide in standard research vial formats. Contact our research team for current batch specifications, availability, and technical documentation.
Glucagon is a counter-regulatory hormone that increases hepatic glucose output and, at supraphysiological levels, increases energy expenditure. In isolation, GCGR agonism is counterproductive in metabolic models. When co-administered with GLP-1R and GIPR agonism (as in the retatrutide molecule), the net effect observed in research models has been amplified fat oxidation and hepatic lipid clearance without the corresponding hyperglycaemia — a balance that has made the triple agonism concept academically compelling.
Researchers studying the GLP-1/GIP/glucagon receptor axis may also find the following compounds relevant to their experimental designs:
Legal Disclaimer: All compounds supplied by Peptides Lab Ireland are intended exclusively for in-vitro laboratory and scientific research purposes by licensed, qualified researchers. They are not medicines, not licensed therapeutic products, and not for human or veterinary administration. Peptides Lab Ireland does not provide medical advice, treatment recommendations, or dosage guidance for any human or clinical application. This page is produced for informational and academic reference purposes only. Use of any research compound must comply with all applicable Irish and EU legislation, including HPRA regulations and institutional ethics requirements.
Receive News
